Sidley Represents Plexxikon in an Exclusive License Agreement with Novellus for Rights to Early Clinical-Stage Cancer Drug

Sidley represented Plexxikon, a California-based drug discovery company, in a license agreement with cancer biotech company Novellus to research, develop, manufacture and (should it gain approval) exclusively sell worldwide the early clinical-stage BRAF-inhibiting compound for the treatment of solid tumors known as PLX8394. Under the terms of the agreement, Plexxikon will receive an undisclosed upfront payment, additional developmental milestones and royalty payments in exchange for the rights to PLX8394.

The Sidley team included Stephen Abreu (partner, San Francisco) and Longbo Wang (associate, Shanghai).